<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694146</url>
  </required_header>
  <id_info>
    <org_study_id>COX1985</org_study_id>
    <secondary_id>2014-004120-21</secondary_id>
    <nct_id>NCT02694146</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis</brief_title>
  <acronym>COX</acronym>
  <official_title>Clinical Trial Randomized, Double-blind Controlled, Phase III, to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of platelet rich plasma (PRP) in patients with
      coxarthrosis who don´t respond to treatment with NSAIDs, compared to treatment with
      hyaluronic acid (Hylan G-F 20).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EVA scale for pain measure.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>The patient assesses the sensation of pain following a horizontal visual analog scale (EVA) with values between 0 (&quot;no pain&quot;) and the value 100 (&quot;excruciating pain&quot;). The records taken are recorded in the medical record of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Harris Hip Score for pain, function and range of motion measure.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>It is a questionnaire developed to evaluate hip surgery or replacement. It is widely used for evaluation of hip disorders and treatment methods.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC questionnaire for pain, stiffness and joint mobility measure.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>It is a standardized questionnaire, widely used for assessment of both knee and hip osteoarthritis. It consists of five items for assessing pain (range 0-20), two items that assess the stiffness (range 0-8) and 17 items that evaluate the functionality of the joint (range 0-68).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse events.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>All adverse events (AEs) are recorded in the case report data from the time that the patient sign the informed consent, indicating the nature of adverse events and their description in both: the experimental group and the comparator.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Coxarthrosis</condition>
  <arm_group>
    <arm_group_label>PRP (platelet rich plasma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.
For PRP administration:
The injection should be performed at room temperature.
The administration should be carried out under aseptic conditions.
The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
The PRP is injected into the synovial space.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hylan G-F 20 (Synvisc-One ®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).
It is necessary to remove synovial fluid before injecting Hylan G-F 20.
The injection should be performed at room temperature.
The administration should be carried out under aseptic conditions.
The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
The Hylan G-F 20 is injected into the synovial space.
After injecting Hylan G-F 20 the patient should stand 5 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet rich plasma</intervention_name>
    <description>Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).</description>
    <arm_group_label>PRP (platelet rich plasma)</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.</description>
    <arm_group_label>Hylan G-F 20 (Synvisc-One ®)</arm_group_label>
    <other_name>Synvisc-One</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients&gt; 30 years.

          -  Patients who voluntarily express their intention to participate by informed consent.

          -  Diagnosis of coxarthrosis who have failed conservative treatments for 6 months

          -  Women of childbearing potential must have a negative pregnancy test during screening
             and must agree to use adequate contraception (or two contraceptive methods, of which
             one is barrier) while participating in the trial.

        Exclusion Criteria:

          -  Treatment with infiltrations 3 months prior to the study

          -  Prior treatment with NSAIDs 24h prior to extraction

          -  Pre-Surgical Treatment of Hip affects

          -  Diabetics

          -  Severe liver or kidney disease at the time of extraction

          -  Thrombocytopenia (&lt;100,000 platelets / ml) at baseline

          -  Anemia (Hb 9 &lt;mg / dl) at baseline

          -  Hyaluronic acid Allergy

          -  History crystal arthropathy, inflammatory arthritis or neuropathic arthropathy.

          -  Acetabular protrusions

          -  History of infectious arthritis

          -  Excessive deformity (acetabular dysplasia, Perthes)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Javier Roca Ruiz, Graduate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María del Mar Villanova, Graduate</last_name>
    <email>mariadelmarvillanova@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María del Mar Benjumea Vargas, Graduate</last_name>
    <phone>955040450</phone>
    <email>gestionensayosclinicos.fps@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Vaquero Cervino, graduate</last_name>
      <email>eduvaquero@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Javier Roca Ruiz, graduate</last_name>
      <email>luisjrocaruiz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria del Mar Villanova López, graduate</last_name>
      <phone>626309591</phone>
      <email>mariadelmarvillanova@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Javier Roca Ruiz, graduate</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria del Mar Villanova López, graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomás Perez Cervera, graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Núñez Núñez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Pérez Pérez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manolo Camean, Chemistry</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet-rich plasma (PRP)</keyword>
  <keyword>hyaluronic acid (Hylan G-F 20).</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>WOMAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

